Capricor Therapeutics (CAPR) vs Tectonic Therapeutic (TECX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Tectonic Therapeutic (TECX) has outperformed Capricor Therapeutics (CAPR) over the past year, gaining 52.3% versus a gain of 8.0%. Over five years, CAPR leads with a +104.5% price change compared with -67.4% for TECX. Capricor Therapeutics is the larger company by market cap ($459.0 million vs $425.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CAPR | TECX |
|---|---|---|
| Share price | $7.90 | $21.76 |
| Market cap | $459.01M | $425.39M |
| 1-day change | -2.53% | -4.18% |
| YTD return | -71.93% | +8.87% |
| 1-year return | +8.00% | +52.31% |
| 5-year return | +104.55% | -67.37% |
| EPS (TTM) | $-2.45 | $-4.57 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $40.37 | $39.53 |
| 52-week low | $2.96 | $15.32 |
| Distance from 52-week high | -80.44% | -44.95% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +241.99% | +252.16% |
| Average volume | 6.85M | 220.39K |
| Shares outstanding | 58.14M | 19.55M |
| Employees | 231 | 60 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TECX has outperformed CAPR by 44.3 percentage points over the past year.
About Capricor Therapeutics
CAPR stock →Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD.
Health Care · Biotechnology: Pharmaceutical Preparations · 231 employees
About Tectonic Therapeutic
TECX stock →Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 60 employees
CAPR vs TECX FAQ
Which is bigger, Capricor Therapeutics or Tectonic Therapeutic?
Capricor Therapeutics (CAPR) is larger, with a market capitalization of $459.01M compared with $425.39M for Tectonic Therapeutic (TECX).
Which stock has performed better over the past year, CAPR or TECX?
TECX returned +52.31% over the past 12 months, compared with +8.00% for CAPR (price return, excluding dividends). Past performance does not predict future results.
Are Capricor Therapeutics and Tectonic Therapeutic in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Capricor Therapeutics and Biotechnology: Biological Products (No Diagnostic Substances) for Tectonic Therapeutic.